Rhian Touyz

Kidney Research Centre, Ottawa Health Research institute, Canada

Rhian Touyz is affiliated with the Department of Medicine, University of Ottawa. She is the Canada Research Chair in Hypertension at the Kidney Research Centre there. She is a Senior Scientist at the OHRI and physician in the Division of Nephrology.

Her main focus of research relates to molecular and cellular mechanisms of hypertension. Her areas of study include clinical and experimental hypertension, hypertension in renal disease, signal transduction, oxidative stress, ion transport, vascular remodeling and insulin resistance and diabetes. She has a particular interest in translational research.

Professor Touyz is on the Executive Board of the Canadian Hypertension Education Program (CHEP), she co-chairs the Recommendations Task Force of CHEP and she is the President of the Canadian Hypertension Society. She is the Scientific Officer of the Cardiovascular committees at the Canadian Institutes of Health Research and the Heart and Stroke Foundation of Canada and she is a member of the Microcirculation and Hypertension Review panel of the National Institutes of Health in the USA. Professor Touyz is Associate Editor of the journals Clinical Science and the Journal of the American Society of Hypertension and she is on the on the Editorial Boards of Hypertension, Journal of Hypertension, American Journal of Physiology, Magnesium, Current Hypertension Reviews, Circulation Research and Current Opinion in Nephrology and Hypertension. She has received numerous academic and research awards, including 2005 Dahl Lecture Award by the American Heart Association and the 2006 Grace A Goldsmith Award, American Society of Nutrition in recognition of her contributions to hypertension research.

Any competing interests declared are displayed with individual evaluations.

Faculty Member: Cardiovascular Disorders > Hypertension (since 12 December 2005)

All recent recommendations

• 6.6
  Weight loss with a low-carbohydrate, Mediterranean, or low-fat diet.
  Recommended by Pagona Lagiou, Rhian Touyz, Seth Field
  
• 3.0
  Nox4 oxidase overexpression specifically decreases endogenous Nox4 mRNA and inhibits angiotensin II-induced adventitial myofibroblast migration.
  Recommended by Rhian Touyz
  
• 6.0
  Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies.
  Recommended by Rhian Touyz
  
• 3.0
  Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial.
  Recommended by Rhian Touyz
  
• 6.0
  Prorenin induces intracellular signaling in cardiomyocytes independently of angiotensin II.
  Recommended by Rhian Touyz
  
• 6.0
  Effect of regular phosphodiesterase type 5 inhibition in hypertension.
  Recommended by Rhian Touyz
  
• 3.0
  Valsartan, blood pressure reduction, and C-reactive protein: primary report of the Val-MARC trial.
  Recommended by Rhian Touyz
  
• 3.0
  Effects of childhood primary hypertension on carotid intima media thickness: a matched controlled study.
  Recommended by Rhian Touyz
  
• 6.0
  Vitamin C and vitamin E in pregnant women at risk for pre-eclampsia (VIP trial): randomised placebo-controlled trial.
  Recommended by Rhian Touyz
  
• 6.0
  High-density lipoproteins enhance progenitor-mediated endothelium repair in mice.
  Recommended by Rhian Touyz
  
• 6.0
  Impairment of in vitro and in vivo heart function in angiotensin-(1-7) receptor MAS knockout mice.
  Recommended by Rhian Touyz
  
• 6.0
  Serum uric acid is associated with microalbuminuria in prehypertension.
  Recommended by Rhian Touyz